Anthem Expands Alzheimer’s Blood Test Coverage as Quanterix Validates Multi-Biomarker Approach
Event summary
- Anthem Blue Cross and Blue Shield begins commercial coverage for Quanterix’s LucentAD® Complete blood test for Alzheimer’s disease starting July 1, 2026.
- New peer-reviewed study shows LucentAD® Complete demonstrates diagnostic parity with immunoprecipitation mass spectrometry (IP-MS) while reducing diagnostic ambiguity by approximately three-fold.
- Quanterix presents new data at AAIC 2026 highlighting the role of multi-biomarker testing in supporting patient triage and earlier clinical decision-making.
The big picture
Quanterix’s milestones mark a critical shift in Alzheimer’s diagnostics, moving from research labs to mainstream clinical practice. Anthem’s coverage decision—impacting 40 million members—signals growing insurer acceptance of blood-based tests as viable alternatives to invasive procedures. The validation against IP-MS and real-world data presented at AAIC 2026 strengthen Quanterix’s position in a market increasingly prioritizing early, accessible diagnostics.
What we're watching
- Adoption Pace
- How quickly Anthem’s coverage decision will drive broader insurer adoption of blood-based Alzheimer’s diagnostics.
- Clinical Integration
- Whether the multi-biomarker approach can sustain its diagnostic advantages in real-world clinical settings.
- Competitive Response
- The pace at which competitors will introduce similar multi-analyte tests to challenge Quanterix’s market position.
Related topics